Acitretin
As of the edition of 20 October 2026, Acitretin is a small molecule: marketed, first approved in 1988 (FR); acts on RARA, RARB and RARG and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2018
- Kind
- Small molecule
- Brand name
- Soriatane
- First approved
- 12 September 1988 (FR)
- Approvals on record
- 9 in 5 regions
- Holder of the most recent approval
- TEVA FARMACĂUTICA LTDA.; 5 holders in all
- Registered trials
- 21, 7 stopped early
- Disease areas
- Skin and connective tissue; Cancer; Immune system; Infections; Urinary and reproductive; Digestive system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
6 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product6 company-target rows are on route B because of Acitretin.
See the 6 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 4 | 0 | 1 |
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 3 | 1 | 0 | 1 |
| Phase 3 | 2 | 2 | 0 | 0 |
| Phase 4 | 9 | 2 | 1 | 4 |
| All trials | 21 |